Anti-Amyloid Precursor Protein antibody [Y188],Abcam,AB32136
Anti-Amyloid Precursor Protein antibody [Y188] (ab32136) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in ICC/IF, IHC-P, IP and WB. Anti-Amyloid Precursor Protein antibody [Y188] (ab32136) was first used in a scientific publication in 1984 and has been cited over 242 times in peer reviewed journals. It's performance in Western Blot in human, mouse and rat samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Amyloid Precursor Protein antibody [Y188] (ab32136) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-Amyloid Precursor Protein antibody [Y188] (ab32136) has been confirmed by Western Blot testing in Amyloid Precursor Protein knockout HEK-293T cells. Anti-Amyloid Precursor Protein antibody [Y188] (ab32136) has 8 independent reviews from customers. Anti-Amyloid Precursor Protein antibody [Y188] (ab32136) specifically detects Amyloid Precursor Protein (UniProt ID: P05067; Molecular weight: 86kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone Y188 - ab220793 . Antibody clone Y188 is also available pre-conjugated to a variety of labels for your convenience - HRP, PE, Alexa Fluor ® 488, Alexa Fluor ® 647, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555, Alexa Fluor ® 750 ( ab199550 , ab208744 , ab310994 , ab311119 , ab311748 , ab313028 , ab313229 , ab321579 ). APP (Amyloid Precursor Protein) is a critical protein in neuro research, particularly for its role in the pathogenesis of Alzheimer's disease (AD). It is cleaved to produce amyloid-beta (beta-Amyloid, A-beta) peptides, which aggregate to form plaques, a hallmark of AD pathology. Researchers use APP to study the mechanisms of amyloid-beta production, aggregation and its effects on neuronal function and survival, making it essential for understanding and developing treatments for AD. Its expression and processing are key factors in the progression of neurodegenerative conditions. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
WB, IP, ICC/IF, IHC-P
Platform ID
BAB764878413
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed : 25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed : 17062754, PubMed : 23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.. Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis. See full target information APP
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.